EA201991100A1 - TMA CELL COMPOSITION WITH CHIMERA ANTIGENIC RECEPTOR FOR BCMA (OPTIONS) - Google Patents

TMA CELL COMPOSITION WITH CHIMERA ANTIGENIC RECEPTOR FOR BCMA (OPTIONS)

Info

Publication number
EA201991100A1
EA201991100A1 EA201991100A EA201991100A EA201991100A1 EA 201991100 A1 EA201991100 A1 EA 201991100A1 EA 201991100 A EA201991100 A EA 201991100A EA 201991100 A EA201991100 A EA 201991100A EA 201991100 A1 EA201991100 A1 EA 201991100A1
Authority
EA
Eurasian Patent Office
Prior art keywords
bcma
chimera
tma
options
cell composition
Prior art date
Application number
EA201991100A
Other languages
Russian (ru)
Inventor
Трэвис Куигли
Роберт Росс
Original Assignee
Блубёрд Био, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Блубёрд Био, Инк. filed Critical Блубёрд Био, Инк.
Priority claimed from PCT/US2017/059989 external-priority patent/WO2018085690A1/en
Publication of EA201991100A1 publication Critical patent/EA201991100A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Настоящее изобретение относится к улучшенным композициям T-клеток с CAR к BCMA для адаптивной T-клеточной терапии рецидивирующей/рефрактерной множественной миеломы.The present invention relates to improved T-cell compositions with CAR for BCMA for adaptive T-cell therapy of recurrent / refractory multiple myeloma.

EA201991100A 2017-06-02 2017-11-03 TMA CELL COMPOSITION WITH CHIMERA ANTIGENIC RECEPTOR FOR BCMA (OPTIONS) EA201991100A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762514401P 2017-06-02 2017-06-02
PCT/US2017/059989 WO2018085690A1 (en) 2016-11-04 2017-11-03 Anti-bcma car t cell compositions

Publications (1)

Publication Number Publication Date
EA201991100A1 true EA201991100A1 (en) 2019-09-30

Family

ID=68000206

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991100A EA201991100A1 (en) 2017-06-02 2017-11-03 TMA CELL COMPOSITION WITH CHIMERA ANTIGENIC RECEPTOR FOR BCMA (OPTIONS)

Country Status (1)

Country Link
EA (1) EA201991100A1 (en)

Similar Documents

Publication Publication Date Title
MX2019005277A (en) Anti-bcma car t cell compositions.
CY1125032T1 (en) CHIMARIC ANTIGONE RECEPTOR MND HYPOMOTOR
PH12017501413A1 (en) Substituted nucleoside derivatives useful as anticancer agents
PH12017500660A1 (en) Novel compositions, uses and methods for making them
EA201990208A1 (en) CHIMER ANTIGENIC RECEPTORS AIMED AT BCMA AND WAYS OF THEIR APPLICATION
PH12018502535B1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
MX2018006217A (en) Apelin receptor agonists and methods of use.
EA201791310A1 (en) CHEMERIC ANTIGEN RECEPTORS TO BCMA
MX2017001079A (en) Bcma chimeric antigen receptors.
PH12016501192A1 (en) Tetrahydropyridopyrazines modulators of gpr6
TR201900071T4 (en) Composition for Controlled Ovarian Stimulation
EA201891336A1 (en) Heteroarylhydroxypyrimidinones as agonists of the APJ receptor
MX2022010755A (en) Kinase inhibitors and uses thereof.
ZA202309446B (en) Rapamycin analogs and uses thereof
UA113879C2 (en) HUMANIZED TRK ANTITILE ANTIBODY
EP3795578A3 (en) Hydroxysteroid compounds, their intermediates, process of preparation, composition and uses thereof
PH12019502694A1 (en) Anti-trkb antibodies
MX2017011116A (en) Novel compositions, uses and methods for making them.
PH12016501613B1 (en) Pyrazines modulators of gpr6
MX2016009219A (en) Substituted bicyclic heteroaryl compounds as rxr agonists.
MX2019008375A (en) Thiobenzoimidazole as fungicides.
EA201991100A1 (en) TMA CELL COMPOSITION WITH CHIMERA ANTIGENIC RECEPTOR FOR BCMA (OPTIONS)
GB201905218D0 (en) Eletrode compositions
PH12019500801A1 (en) Structures and mechanism for the design of highly potent glucocorticoids